RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Fusion Pharm Stock

Fusion Pharm Revenue 2024

Fusion Pharm Revenue

808,400 USD

Ticker

FSPM

ISIN

US36113H1005

WKN

A1H9CD

In 2024, Fusion Pharm's sales reached 808,400 USD, a 255.43% difference from the 227,440 USD sales recorded in the previous year.

The Fusion Pharm Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
20120.8183,67
20110.2330,55
19970.03-680,00
19960.88-236,92
19957.99-13,73
19948.28-2,86

Fusion Pharm Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Fusion Pharm, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Fusion Pharm from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Fusion Pharm’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Fusion Pharm. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Fusion Pharm’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Fusion Pharm’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Fusion Pharm’s growth potential.

Fusion Pharm Revenue, EBIT and net profit per share

DateFusion Pharm RevenueFusion Pharm EBITFusion Pharm Net Income
2012808,400 undefined298,440 undefined265,210 undefined
2011227,440 undefined-327,640 undefined-402,380 undefined
199730,000 undefined-304,000 undefined-406,000 undefined
1996883,000 undefined-2.25 M undefined-883,000 undefined
19957.99 M undefined-2.52 M undefined-2.28 M undefined
19948.28 M undefined-982,000 undefined-1.16 M undefined

Fusion Pharm stock margins

The Fusion Pharm margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fusion Pharm. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fusion Pharm.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Fusion Pharm's sales revenue. A higher gross margin percentage indicates that the Fusion Pharm retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Fusion Pharm's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Fusion Pharm's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Fusion Pharm's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Fusion Pharm. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Fusion Pharm's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Fusion Pharm Margin History

Fusion Pharm Gross marginFusion Pharm Profit marginFusion Pharm EBIT marginFusion Pharm Profit margin
201283.67 %36.92 %32.81 %
201130.55 %-144.06 %-176.92 %
1997-680 %-1,013.33 %-1,353.33 %
1996-236.92 %-255.27 %-100 %
1995-13.73 %-31.56 %-28.5 %
1994-2.86 %-11.87 %-14.03 %

Fusion Pharm Aktienanalyse

What does Fusion Pharm do?

Fusion Pharm Inc is a well-known company in the agricultural industry that operates in various business sectors. It was founded in 2010 by Scott Dittman with the idea of improving agricultural efficiency through the use of innovative technologies. Fusion Pharm has gradually built different business areas focused on the development and marketing of products for optimizing agriculture. One of Fusion Pharm's core areas is the production of modular cultivation systems for plants that utilize cutting-edge technologies. These systems, called "PharmaCubes," are designed to provide optimal conditions for plants and achieve higher crop yields. They are particularly intended for use in urban spaces and other environments where traditional cultivation methods may not be feasible. The advantage of these systems lies in their scalability, and they are optimized for indoor use. Another important business area for Fusion Pharm is the production of fertilizers and other agricultural chemicals. These products are marketed under the brand name "Agritabs" and are aimed at promoting healthier plant growth and higher crop yields. The agricultural chemicals are made from natural raw materials, making them more environmentally friendly than many other products on the market. They are intended for use in various industries, including agriculture, gardening and landscaping, and the food industry. In addition to manufacturing and supplying cultivation systems, Fusion Pharm also operates in the production and distribution of natural fertilizers and other agricultural chemicals. The company has also undertaken a pilot project for closed-room fish farming and established itself in the aquaculture industry. In recent years, the company has pursued an aggressive acquisition strategy to expand into new business fields. One of these acquisitions was the takeover of the cloud-based software company "CannaCube," which has developed a management system for cannabis cultivation. Through the acquisition of CannaCube, Fusion Pharm has now positioned its portfolio for the growing cannabis industry. The company has made a name for itself in the agricultural industry by optimizing existing processes for sustainable and efficient plant development. With its innovative technology and products, the company contributes to greater efficiency and a more environmentally friendly agricultural industry. Fusion Pharm ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Fusion Pharm's Sales Figures

The sales figures of Fusion Pharm originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Fusion Pharm’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Fusion Pharm's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Fusion Pharm’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Fusion Pharm stock

How much revenue did Fusion Pharm generate this year?

Fusion Pharm has achieved a revenue of 808,400 USD this year.

How much was the turnover of the company Fusion Pharm compared to the previous year?

The revenue of Fusion Pharm has increased by 255.43% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Fusion Pharm?

The revenue of Fusion Pharm is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Fusion Pharm measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Fusion Pharm so important for investors?

The revenue of Fusion Pharm is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Fusion Pharm pay?

Over the past 12 months, Fusion Pharm paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fusion Pharm is expected to pay a dividend of 0 USD.

What is the dividend yield of Fusion Pharm?

The current dividend yield of Fusion Pharm is .

When does Fusion Pharm pay dividends?

Fusion Pharm pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fusion Pharm?

Fusion Pharm paid dividends every year for the past 0 years.

What is the dividend of Fusion Pharm?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fusion Pharm located?

Fusion Pharm is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von Fusion Pharm kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fusion Pharm from 11/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did Fusion Pharm pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Fusion Pharm in the year 2023?

In the year 2023, Fusion Pharm distributed 0 USD as dividends.

In which currency does Fusion Pharm pay out the dividend?

The dividends of Fusion Pharm are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Fusion Pharm

Our stock analysis for Fusion Pharm Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fusion Pharm Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.